Changing concepts of hormone receptor-positive advanced breast cancer therapy.

[1]  F. Cardoso,et al.  A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. , 2013, Cancer treatment reviews.

[2]  A. Lluch,et al.  Finding the right dose of fulvestrant in breast cancer. , 2013, Cancer treatment reviews.

[3]  M. Ellis,et al.  Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study , 2012, Breast Cancer Research and Treatment.

[4]  F. André,et al.  mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Gnant,et al.  Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. , 2012, European journal of cancer.

[6]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Robert B Livingston,et al.  Combination anastrozole and fulvestrant in metastatic breast cancer. , 2012, The New England journal of medicine.

[8]  A. Ravaud,et al.  Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Ljung,et al.  Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Bergh,et al.  FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Forbes,et al.  The sequential use of endocrine treatment for advanced breast cancer: where are we? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Howell,et al.  2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747) , 2012 .

[14]  Yuan Qi,et al.  Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[16]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[17]  R. O'Regan,et al.  mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy , 2011, Expert opinion on therapeutic targets.

[18]  H. Burstein.  Novel agents and future directions for refractory breast cancer. , 2011, Seminars in oncology.

[19]  John M S Bartlett,et al.  Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[21]  M. Dowsett,et al.  Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. , 2010, European journal of cancer.

[22]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Neven,et al.  Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) , 2010, Breast Cancer Research and Treatment.

[24]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[25]  D. Allred.  Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer , 2010, Modern Pathology.

[26]  David M Sabatini,et al.  mTOR and cancer: many loops in one pathway. , 2009, Current opinion in cell biology.

[27]  L. Skoog,et al.  Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer , 2010, Breast Cancer Research and Treatment.

[28]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Ellis,et al.  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Dranitsaris,et al.  Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  I. Ishiwata,et al.  Therapeutic strategy targeting the mTOR–HIF‐1α–VEGF pathway in ovarian clear cell adenocarcinoma , 2009, Pathology international.

[33]  Cynthia X. Ma,et al.  Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT , 2009 .

[34]  M. Clemons,et al.  Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[35]  M. Piccart,et al.  Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Piccart,et al.  First-Line Treatment of Metastatic Breast Cancer , 2006 .

[37]  M. Piccart,et al.  Facts and controversies in systemic treatment of metastatic breast cancer. , 2004, The oncologist.

[38]  R. Chlebowski,et al.  Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Robertson,et al.  Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. , 2003, European journal of cancer.

[41]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Ghersi,et al.  Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. , 2003, The Cochrane database of systematic reviews.

[43]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[46]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma , 2001, Cancer.

[47]  R. Blamey,et al.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Anthony Howell,et al.  Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma , 1998, Cancer.

[49]  L. Norton,et al.  Metastatic breast cancer. Length and quality of life. , 1991, The New England journal of medicine.

[50]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .